HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin (Q42925898)

11 November 2017

title

HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin (English)

1 reference

11 November 2017

HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin (English)

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

23 June 2024

main subject

cardiovascular disease

1 reference

1 reference

A. G. Olsson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739153

23 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20739153

23 June 2024

publication date

23 August 2010

1 reference

full work available at URL

11 November 2017

https://api.elsevier.com/content/article/PII:S0939475310001705?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

https://api.elsevier.com/content/article/PII:S0939475310001705?httpAccept=text/plain

23 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Nutrition, Metabolism, and Cardiovascular Diseases

23 June 2024

published in

1 reference

11 November 2017

volume

20

1 reference

11 November 2017

issue

8

1 reference

11 November 2017

page(s)

553-557

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

11 November 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

23 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

23 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Extended-release niacin or ezetimibe and carotid intima-media thickness.

23 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study

23 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

The HALTS trial--halting atherosclerosis or halted too early?

23 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Statin therapy with ezetimibe or niacin in high-risk patients

23 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

23 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

23 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

23 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology

23 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

23 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

23 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

23 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors

23 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

23 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Validation of a questionnaire to assess niacin-induced cutaneous flushing

23 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man

23 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

23 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

23 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.NUMECD.2010.07.003

23 June 2024

Identifiers

1 reference

11 November 2017

1 reference